当前位置:首页 - 行情中心 - 千金药业(600479) - 财务分析 - 现金流量表

千金药业

(600479)

  

流通市值:47.96亿  总市值:49.15亿
流通股本:4.19亿   总股本:4.29亿

现金流量表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金3,819,142,909.62,721,830,445.241,850,032,480.06845,525,998.14
收到其他与经营活动有关的现金341,089,835.45193,880,823.09126,769,622.1946,917,009.87
经营活动现金流入的平衡项目0000
经营活动现金流入小计4,160,232,745.052,915,711,268.331,976,802,102.25892,443,008.01
购买商品、接受劳务支付的现金1,691,805,056.81,297,565,808.15956,463,740.95384,939,234.06
支付给职工以及为职工支付的现金692,068,857.64556,256,838.14414,157,663.23275,240,891.11
支付的各项税费329,569,797.75258,005,444.1213,489,716.2690,476,019.54
支付其他与经营活动有关的现金1,003,673,869.26729,848,913.49488,789,373.07335,826,338.36
经营活动现金流出的平衡项目0000
经营活动现金流出小计3,717,117,581.452,841,677,003.882,072,900,493.511,086,482,483.07
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额443,115,163.674,034,264.45-96,098,391.26-194,039,475.06
二、投资活动产生的现金流量:
收回投资收到的现金1,020,400,008.19970,400,008.19788,434,080.06670,000,000.03
取得投资收益收到的现金10,817,511.0410,817,511.0410,473,761.043,552,699.4
处置固定资产、无形资产和其他长期资产收回的现金净额56,28256,28200
投资活动现金流入的平衡项目0000
投资活动现金流入小计1,031,273,801.23981,273,801.23798,907,841.1673,552,699.43
购建固定资产、无形资产和其他长期资产支付的现金43,988,637.7637,702,317.2145,637,467.2217,970,795.04
投资支付的现金402,000,000352,000,000352,000,000302,000,000
投资活动现金流出的平衡项目0000
投资活动现金流出小计445,988,637.76389,702,317.21397,637,467.22319,970,795.04
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额585,285,163.47591,571,484.02401,270,373.88353,581,904.39
三、筹资活动产生的现金流量:
吸收投资收到的现金439,200439,200439,200439,200
取得借款收到的现金42,145,683.7532,145,683.7532,145,683.750
收到其他与筹资活动有关的现金14,740,786.69000
筹资活动现金流入平衡项目0000
筹资活动现金流入小计57,325,670.4432,584,883.7532,584,883.75439,200
偿还债务支付的现金50,722,242.3648,522,242.3648,522,242.360
分配股利、利润或偿付利息支付的现金180,365,251.08174,560,963.83124,479,742.59428,874.14
其中:子公司支付给少数股东的股利、利润32,477,739.6718,318,581.1718,318,581.17-
支付其他与筹资活动有关的现金28,241,480.333,382,5001,406,0000
筹资活动现金流出平衡项目0000
筹资活动现金流出小计259,328,973.77226,465,706.19174,407,984.95428,874.14
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-202,003,303.33-193,880,822.44-141,823,101.210,325.86
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额826,397,023.74471,724,926.03163,348,881.42159,552,755.19
加:期初现金及现金等价物余额1,101,935,114.451,101,935,114.451,101,935,114.451,103,550,818.92
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额1,928,332,138.191,573,660,040.481,265,283,995.871,263,103,574.11
补充资料:
净利润395,016,882.42-144,330,228.3-
资产减值准备2,571,229.74-162,939.82-
固定资产和投资性房地产折旧69,606,315.95-34,281,594.47-
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧69,606,315.95-34,281,594.47-
无形资产摊销11,137,359.87-4,003,858.14-
长期待摊费用摊销18,532,723.98-8,377,201.68-
处置固定资产、无形资产和其他长期资产的损失0-0-
固定资产报废损失944,341.28-139,910.32-
公允价值变动损失1,597,097.03-5,090,050.04-
财务费用1,668,222.98-1,968,453.17-
投资损失-17,469,067.27--11,603,222.61-
递延所得税-2,776,233.25--2,028,054.63-
其中:递延所得税资产减少-3,378,356.78--2,879,243.92-
递延所得税负债增加602,123.53-851,189.29-
存货的减少62,286,557.58-18,154,665.77-
经营性应收项目的减少-8,686,387.69--125,882,966.39-
经营性应付项目的增加-132,493,716.28--194,386,592.27-
现金的期末余额1,928,332,138.19-1,265,283,995.87-
减:现金的期初余额1,101,935,114.45-1,101,935,114.45-
公告日期2024-04-122023-10-282023-08-252023-04-29
审计意见(境内)标准无保留意见
TOP↑